Collegium Pharmaceutical, Inc.
COLL
$35.76
$0.962.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 16.96M | 31.51M | 11.98M | 2.42M | 12.54M |
| Total Depreciation and Amortization | 56.40M | 56.51M | 56.61M | 56.56M | 56.51M |
| Total Amortization of Deferred Charges | 1.28M | 1.34M | 1.36M | 1.37M | 1.42M |
| Total Other Non-Cash Items | 14.58M | -2.42M | 8.36M | 10.75M | -2.64M |
| Change in Net Operating Assets | 33.83M | -8.50M | -5.86M | -15.70M | 16.81M |
| Cash from Operations | 123.05M | 78.44M | 72.44M | 55.40M | 84.64M |
| Capital Expenditure | -689.00K | -188.00K | -65.00K | -798.00K | -570.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.38M | -30.68M | -2.85M | -8.88M | -11.19M |
| Cash from Investing | -20.07M | -30.87M | -2.92M | -9.68M | -11.76M |
| Total Debt Issued | 565.18M | -- | -- | -- | 11.83M |
| Total Debt Repaid | -587.12M | -16.15M | -16.15M | -16.15M | -16.15M |
| Issuance of Common Stock | 985.00K | 2.29M | 308.00K | 2.06M | 173.00K |
| Repurchase of Common Stock | -861.00K | -964.00K | -25.53M | -10.59M | -25.30M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -7.00M | -555.00K | -11.83M |
| Cash from Financing | -21.82M | -14.82M | -48.37M | -25.24M | -41.28M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 81.16M | 32.75M | 21.15M | 20.48M | 31.61M |